Journal
CURRENT DIABETES REPORTS
Volume 10, Issue 2, Pages 101-107Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-010-0095-5
Keywords
Glucosuria; SGLT2; Hyperglycemia; Glucose
Categories
Ask authors/readers for more resources
Hyperglycemia is important in the development of microvascular and macrovascular complications from type 2 diabetes. Although there are many oral therapies available to help ameliorate hyperglycemia, it has been found that the competitive inhibition of the sodium-D-glucose cotransporter-2 (SGLT2) in the kidney may be a promising alternative treatment reducing hyperglycemia and potentially helping to lower the risk of diabetes complications. This article reviews clinical trials that have revealed favorable responses to many glycemic and metabolic parameters with SGLT2 inhibition, both as monotherapy and as an adjunct to insulin and oral antidiabetic agents. Additional studies are necessary to further determine the efficacy and long-term safety of SGLT2 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available